HomeCompareCNVVY vs MRK

CNVVY vs MRK: Dividend Comparison 2026

CNVVY yields 2.51% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CNVVY wins by $176.78M in total portfolio value· pulled ahead in Year 2
10 years
CNVVY
CNVVY
● Live price
2.51%
Share price
$11.56
Annual div
$0.29
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$176.83M
Annual income
$164,256,279.23
Full CNVVY calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — CNVVY vs MRK

📍 CNVVY pulled ahead of the other in Year 2

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCNVVYMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CNVVY + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CNVVY pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CNVVY
Annual income on $10K today (after 15% tax)
$213.24/yr
After 10yr DRIP, annual income (after tax)
$139,617,837.35/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, CNVVY beats the other by $139,609,508.94/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CNVVY + MRK for your $10,000?

CNVVY: 50%MRK: 50%
100% MRK50/50100% CNVVY
Portfolio after 10yr
$88.45M
Annual income
$82,133,038.69/yr
Blended yield
92.86%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

CNVVY
Analyst Ratings
6
Buy
Consensus: Buy
Altman Z
4.0
Piotroski
7/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CNVVY buys
0
MRK buys
0
No recent congressional trades found for CNVVY or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCNVVYMRK
Forward yield2.51%2.76%
Annual dividend / share$0.29$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%32.7%
Portfolio after 10y$176.83M$56.8K
Annual income after 10y$164,256,279.23$9,798.13
Total dividends collected$175.87M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: CNVVY vs MRK ($10,000, DRIP)

YearCNVVY PortfolioCNVVY Income/yrMRK PortfolioMRK Income/yrGap
1$11,202$501.73$11,206$366.19$4.00MRK
2← crossover$13,036$1,050.51$12,650$502.35+$386.00CNVVY
3$16,234$2,285.17$14,407$694.19+$1.8KCNVVY
4$22,690$5,319.08$16,585$967.82+$6.1KCNVVY
5$38,174$13,895.72$19,342$1,363.89+$18.8KCNVVY
6$84,544$43,698.21$22,913$1,947.19+$61.6KCNVVY
7$271,358$180,896.29$27,662$2,823.89+$243.7KCNVVY
8$1,375,621$1,085,267.30$34,159$4,173.35+$1.34MCNVVY
9$11,755,358$10,283,443.92$43,337$6,308.80+$11.71MCNVVY
10$176,834,512$164,256,279.23$56,776$9,798.13+$176.78MCNVVY

CNVVY vs MRK: Complete Analysis 2026

CNVVYStock

ConvaTec Group Plc develops, manufactures, and markets medical products and technologies worldwide. It offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, immobility, and venous disease, as well as from traumatic injury, burns, invasive surgery, and other causes. The company also provides devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, bladder cancer, obesity, and other causes. In addition, it offers continence and critical care products, including intermittent urinary catheters; and products for people with urinary continence issues related to spinal cord injuries, multiple sclerosis, spina bifida, and other urological disorders, as well as devices and products used in intensive care units and hospital settings. Further, the company provides advanced systems for managing acute fecal incontinence, as well as for monitoring urine production output and intra-abdominal pressure; and various disposable medical devices, such as wound drainage systems, urine collection bags and catheters, airway management and oxygen/aerosol therapy devices, suction handles and tubes, gastroenterology tubes, and securement devices. Additionally, it offers disposable infusion sets to manufacturers of insulin pumps for diabetes, as well as similar pumps that are used in continuous infusion treatments for other conditions; and various products to hospital and home healthcare markets. The company sells its products to pharmacies, hospitals, and other acute and post-acute healthcare service providers directly or through distributors and wholesalers. It serves a range of customers, including healthcare providers, patients, and manufacturers. The company was founded in 1978 and is headquartered in Reading, the United Kingdom.

Full CNVVY Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this CNVVY vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CNVVY vs SCHDCNVVY vs JEPICNVVY vs OCNVVY vs KOCNVVY vs MAINCNVVY vs JNJCNVVY vs ABBVCNVVY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.